Aug. 13 /2008
 Accuray Incorporated a global leader in the field of radiosurgery, announced today
that emerging clinical data continues to support CyberKnife radiosurgery for
the treatment of lung cancer, following a study published in the July 2008
issue of Clinical Lung Cancer. As scientific evidence mounts, physician usage
and patient demand are increasing dramatically -- over the past 12 month
period, the number of lung patients treated with the CyberKnife System has
grown by nearly 50 percent and more than 6,000 lung cancer patients have been
treated to date.

The study, titled "Fractionated Stereotactic Body Radiation Therapy in the
Treatment of Primary, Recurrent, and Metastatic Lung Tumors," was conducted at
the University of Pittsburgh Medical Center (UPMC) in Pittsburgh, Pa., and
followed three patient populations over an average 12 month period: 1)
patients with primary stage I non-small cell lung cancer, 2) patients whose
cancer recurred after it was surgically removed, and 3) patients with
metastatic tumors in the lung. All patients were treated with CyberKnife
radiosurgery over a three-day period as outpatients. These patients had
limited treatment options because they were medically inoperable (unable to
undergo surgery due to pre-existing medical conditions or prior surgery) or
refused surgery.

The tumor control and survival outcomes were excellent in the first year
following treatment. Control of tumor growth was achieved in 85 percent of
primary cancer patients, 92 percent of recurrent lung cancer patients, and 62
percent of metastatic cancer patients during the first year of follow-up. This
is drastically different from response rates for radiation therapy in this
patient population, which are typically associated with poor local control and
survival rates ranging from 10 to 30 percent at five-year follow-up, as noted
within the study.

Additionally the study reported few of the complications or side effects
that are typical with radiation or other more invasive treatments within the
first 12 months of follow-up.  Both invasive surgery and conventional
radiation therapy can be associated with post-treatment complications that can
negatively impact a patient's quality of life.  In addition, unlike
conventional radiation therapy that is typically delivered over four to six
weeks, patients completed CyberKnife treatment in three short outpatient
visits.  This is extremely significant for patients with a potentially
life-threatening disease because it allows them to preserve their lifestyle
and spend their time with family instead of taking trips to and from the
hospital and spending months in treatment.

"The CyberKnife System's ability to non-invasively treat lung cancer with
favorable local control rates and minimal toxicities make it an important tool
in the fight against lung cancer," said Dwight Heron, M.D., chairman of the
radiation oncology department at UPMC Shadyside. "As demonstrated by our
study, this is particularly important for patients who previously had few or
no other options because it gives them a chance for a positive outcome while
maintaining their quality of life."

UPMC treated all the study participants using the Synchrony(R) Respiratory
Tracking System, which is the only System in the world that can deliver beams
that physically move in real-time with 3D tumor motion. The technology allows
patients to breath normally throughout the treatment, while still achieving
pinpoint precision and minimizing damage to surrounding healthy tissue.
According to the study, Synchrony "can allow for reductions in planning target
volume margins because of less movement uncertainty while maintaining the
desired level of accuracy."

"With each year that clinical studies are completed and published, we see
physician confidence increase and patient demand grow dramatically," said Euan
S. Thomson, Ph.D., president and CEO of Accuray Incorporated. "This increase
in momentum for CyberKnife radiosurgery worldwide is offering physicians a
better way to treat lung cancer and patients a better option for a quick and
complication-free recovery."

According to the American Cancer Society (ACS), lung cancer is the leading
cause of cancer-related deaths in the United States and will account for
approximately 29 percent of all cancer deaths in 2008. In fact, since 1987
more women have died each year from lung cancer than from breast cancer. The
ACS projects that more than 215,000 new cases of lung cancer will be
discovered in 2008, accounting for 15 percent of all cancer diagnoses.